• Patrick M Wieruszewski, Marc Leone, Benjamin Skov Kaas-Hansen, Siddharth Dugar, Matthieu Legrand, Cathrine A McKenzie, Brittany D Bissell Turpin, Antonio Messina, Prashant Nasa, Christa A Schorr, Jan J De Waele, and Ashish K Khanna.
• Department of Pharmacy, Mayo Clinic, Rochester, MN.
• Crit. Care Med. 2024 Apr 1; 52 (4): 521530521-530.

ObjectivesTo provide guidance on the reporting of norepinephrine formulation labeling, reporting in publications, and use in clinical practice.DesignReview and task force position statements with necessary guidance.SettingA series of group conference calls were conducted from August 2023 to October 2023, along with a review of the available evidence and scope of the problem.SubjectsA task force of multinational and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine.InterventionsThe implications of a variation in norepinephrine labeled as conjugated salt (i.e., bitartrate or tartrate) or base drug in terms of effective concentration of norepinephrine were examined, and guidance was provided.Measurements And Main ResultsThere were significant implications for clinical care, dose calculations for enrollment in clinical trials, and results of datasets reporting maximal norepinephrine equivalents. These differences were especially important in the setting of collaborative efforts across countries with reported differences.ConclusionsA joint task force position statement was created outlining the scope of norepinephrine-dose formulation variations, and implications for research, patient safety, and clinical care. The task force advocated for a uniform norepinephrine-base formulation for global use, and offered advice aimed at appropriate stakeholders.Copyright © 2024 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

16 keywords...

hide…